AstraZeneca (AZN.L): FDA accepts NDA submission for selumetinib | Beximco Pharma: First quarter results show continued growth | Tissue Regenix Group plc (TRX.L): Update on loan agreement |
14 Nov 2019
SP Angel Healthcare Conditions
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
SP Angel Healthcare Conditions
AstraZeneca PLC (AZN:LON), 11,948 | Beximco Pharmaceuticals Limited Sponsored GDR RegS (BXP:LON), 37.0 | Tissue Regenix Group plc (TRX:LON), 61.5
- Published:
14 Nov 2019 -
Author:
Vadim Alexandre | Liam Gascoigne-Cohen -
Pages:
3
AstraZeneca (AZN.L): FDA accepts NDA submission for selumetinib | Beximco Pharma: First quarter results show continued growth | Tissue Regenix Group plc (TRX.L): Update on loan agreement |